Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor
This week: we look at EMA’s updated draft Guideline for depression therapeutics, which includes a section on psychedelics; California’s Governor is set to decide the fate of a state-wide decrim. bill, SB-58; MAPS published its second Phase 3 study; and lots more…
Natural Medicine Advisory Bulletin #3: August 2023
Five of six subcommittees plus the full Natural Medicine Advisory Board (NMAB) met in August. Harm Reduction and Public Safety did not meet and was dissolved by the full NMAB on August 18th. Updates from each subcommittee that met, as well as the Natural Medicine Advisory Board, are shared in this Issue.
Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft Guidance; Cybin to Acquire Small Pharma; Usona Publishes Phase 2 Study
This week: big pharma co. Otsuka is set to acquire Mindset in the same week that Cybin announced it would acquire Small Pharma; over 200 responses to FDA’s draft guidance for psychedelic trials; UK cross-party committee recommends rescheduling psychedelics; and lots more…
Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection
This week: will MAPS PBC’s MDMA drug product be called ‘RENSANSE’?; We look at Sage’s Zuranolone flop; DEA throws a potential lifeline to at-home ketamine providers; UK Parliamentary Office publishes note on psychedelics; and lots more…
Natural Medicine Advisory Bulletin #2: July 2023
Five of six subcommittees plus the full NMAB met in July. Updates from each subcommittee that met, as well as the Natural Medicine Advisory Board, are shared in this Issue.
Psychedelic Bulletin #142: Terran’s IP Portfolio; AMA Advocates Against Non-Medical Psychedelics; Couple Receives First Psilocybin Services in Oregon; Mass. Ballot Measure Ramps Up; NIDA and NIMH Directors Opine
This week: we take a deep dive into Terran Biosciences’ IP portfolio and apparent strategy; a psychedelic naive couple are the first people to receive legal psilocybin services in OR; AMA, NIDA and NIMH opine on psychedelics; a psychedelic ballot measure heats up in Mass.; and lots more…